Novo Nordisk announced the global launch of connected insulin pens

| By | Drug Development, Novo Nordisk
0
185

Novo Nordisk announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019.

In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk’s vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche.

The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health® and Glooko, Novo Nordisk aims to seamlessly integrate insulin dosing data from connected pen devices with its partners’ open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).

The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in the first quarter of 2019 and roll out to over 50 countries in the coming years. NovoPen® 6 and NovoPen Echo® Plus will eventually be phased in to replace NovoPen® 5 and NovoPen Echo® in countries where those devices are currently available.

Novo Nordisk will also integrate insulin dosing data with Dexcom CGM data in the coming years. Beyond launching connected durable devices, Novo Nordisk expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019. In the longer term, Novo Nordisk aims to increase the availability of connected pens and offer solutions for personalised treatment guidance.

SOURCE: novo nordisk
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.